Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies...
Date First Received: January 18, 2007
Last Updated: January 18, 2008
Verified by: University of Saskatchewan, January 2008
Clinical Trial Phase: N/A | Start Date: January 2007
Overall Status: Completed
Estimated Enrollment: 12
Brief Summary
Official Title: “Airway Responses to Montelukast and Desloratadine.”
Condition Keyword(s):
Intervention(s):
Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Study Primary Completion Date: August 2007
Intervention(s) in this Clinical Trial
- Drug: Montelukast (10mg) and Desloratadine (5mg)
Outcome Measures for this Clinical Trial
Primary Measures
- Late asthmatic response (maximum percent decrease in FEV1)
Secondary Measures
- Early asthmatic response (maximum percent decrease in FEV1
- Changes in sputum cell/mediator content
- Changes in airway hyperresponsiveness (methacholine PC20)
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- baseline FEV1 > or = 65% predicted
- positive methacholine challenge (i.e. methacholine PC20 < or = 16mg/ml
- positive allergen challenge
Exclusion Criteria:
- negative skin prick test
- lung condition/disease other than asthma
- currently use montelukast and/or desloratadine
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: University of Saskatchewan
Overall Clinical Trial Officials and Contacts
Donald W Cockcroft, MD, FRCP(C) Principal Investigator University of Saskatchew Full Professor
Additional Information
Information obtained from ClinicalTrials.gov on September 04, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00424580
Study ID Number: BIO-REB# 06-232
ClinicalTrials.gov Identifier: NCT00424580
Health Authority: Canada: Health Canada
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
